MEI Pharma Inc (MEIP)
2.92
-0.09
(-2.99%)
USD |
NASDAQ |
Nov 15, 16:00
2.91
-0.01
(-0.34%)
After-Hours: 20:00
MEI Pharma Research and Development Expense (TTM): 16.56M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 16.56M |
| March 31, 2024 | 15.19M |
| December 31, 2023 | 25.07M |
| September 30, 2023 | 36.47M |
| June 30, 2023 | 52.45M |
| March 31, 2023 | 71.72M |
| December 31, 2022 | 78.93M |
| September 30, 2022 | 85.15M |
| June 30, 2022 | 85.64M |
| March 31, 2022 | 80.10M |
| December 31, 2021 | 75.66M |
| September 30, 2021 | 76.36M |
| June 30, 2021 | 69.40M |
| March 31, 2021 | 60.96M |
| December 31, 2020 | 52.04M |
| September 30, 2020 | 38.10M |
| June 30, 2020 | 34.06M |
| March 31, 2020 | 34.24M |
| December 31, 2019 | 34.35M |
| September 30, 2019 | 35.13M |
| June 30, 2019 | 32.30M |
| March 31, 2019 | 28.73M |
| December 31, 2018 | 22.73M |
| September 30, 2018 | 17.10M |
| June 30, 2018 | 17.04M |
| Date | Value |
|---|---|
| March 31, 2018 | 14.65M |
| December 31, 2017 | 13.46M |
| September 30, 2017 | 11.66M |
| June 30, 2017 | 7.237M |
| March 31, 2017 | 9.149M |
| December 31, 2016 | 10.69M |
| September 30, 2016 | 12.23M |
| June 30, 2016 | 13.40M |
| March 31, 2016 | 13.20M |
| December 31, 2015 | 16.55M |
| September 30, 2015 | 20.07M |
| June 30, 2015 | 23.82M |
| March 31, 2015 | 26.46M |
| December 31, 2014 | 25.10M |
| September 30, 2014 | 22.79M |
| June 30, 2014 | 19.33M |
| March 31, 2014 | 14.57M |
| December 31, 2013 | 10.70M |
| September 30, 2013 | 7.634M |
| June 30, 2013 | 6.084M |
| March 31, 2013 | 5.753M |
| December 31, 2012 | 5.70M |
| September 30, 2012 | 5.423M |
| June 30, 2012 | 4.915M |
| March 31, 2012 | 3.976M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
15.19M
Minimum
Mar 2024
85.64M
Maximum
Jun 2022
53.81M
Average
52.45M
Median
Jun 2023
Research and Development Expense (TTM) Benchmarks
| Avid Bioservices Inc | -- |
| Evoke Pharma Inc | 0.0389M |
| Revance Therapeutics Inc | 77.24M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |